We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Long-Read Sequencing Technology to Identify Genetic Contributors of Rare Diseases in Children

By LabMedica International staff writers
Posted on 06 Sep 2024

As genetic sequencing technology advances and becomes more accessible, significant progress has been made in understanding the genetic bases of various diseases. More...

This progress has sparked a proliferation of clinical applications for genetic testing, providing hope and better outcomes for individuals suffering from numerous genetic conditions. Despite these advancements, there remains a significant number of individuals with rare diseases who go undiagnosed, even with cutting-edge genomic testing. To address this, a team of researchers is now employing a novel sequencing approach known as long-read genome sequencing to re-examine the genomes of individuals who previously underwent sequencing without receiving a diagnosis. Long-read sequencing offers a more complete view of the genome, capturing many genetic variants that may be overlooked by traditional sequencing techniques.

At the HudsonAlpha Institute for Biotechnology (Huntsville, AL, USA), researchers are leading the way in using genome sequencing to transform the diagnosis of genetic disorders, particularly in children. Since 2013, the team has sequenced the genomes of nearly 2,000 children, with over 40% revealing genetic insights related to their clinical symptoms. They are now focusing on long-read sequencing, which they believe could provide diagnoses for more children and their families. Preliminary findings indicate that long-read sequencing could identify significant genetic insights in 5-10% of cases previously tested but undiagnosed, potentially improving diagnostic rates for a broad spectrum of pediatric conditions. Given that this technology is still in its early stages, there is considerable scope for further refinement and improvement, which could even further enhance diagnostic success rates as indicated by initial studies.

The research team plans to apply long-read sequencing to re-assess the genomes of over 500 individuals whose previous short-read sequencing did not yield conclusive results. In certain cases, they will also sequence the genomes of the patients' parents to detect both inherited and new genetic variations. Long-read sequencing is particularly adept at identifying types of genetic variations that are not typically detected with short-read sequencing, such as structural variants. These structural variants, which include large deletions, duplications, inversions, translocations, and other complex rearrangements, can disrupt gene function and lead to disease. The limited capability of short-read sequencing to detect these structural variants means that long-read sequencing may uncover additional variants that could explain the symptoms in some patients.

“Long-read sequencing holds immense promise for uncovering the genetic causes of diseases,” said HudsonAlpha Faculty Investigator Greg Cooper, PhD. “My team and I are passionate about making a difference in the lives of individuals and families affected by rare genetic disorders. By pushing the boundaries of genetic research, we hope to shed light on previously hidden genetic variation and provide more accurate and timely diagnoses. Our goal is to empower families with the knowledge they need to navigate their health challenges and build a better future.”

Related Links:
HudsonAlpha Institute for Biotechnology


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.